William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matt Phipps has given his Buy rating due to a combination of factors related to Upstream Bio’s lead asset, verekitug, and its Phase III strategy. He views the decision to pursue a quarterly dosing schedule as the optimal approach to unlock superior efficacy versus existing TSLP competitors, especially Tezspire, rather than stretching to a less frequent regimen that might compromise clinical benefit.
He also highlights supportive Phase II data, where the highest dose showed the strongest lung function gains and post hoc exposure analyses reinforced that efficacy profile across asthma and CRSwNP. In his view, this plan positions verekitug for a potentially best-in-class profile while shifting competitive pressure to rival programs to prove they can match efficacy with less frequent dosing, which collectively underpins his positive outlook on the shares.
Phipps covers the Healthcare sector, focusing on stocks such as Evommune, Inc., Insmed, and Climb Bio. According to TipRanks, Phipps has an average return of 4.9% and a 43.81% success rate on recommended stocks.